Canine hypoadrenocorticism: reduced-dose DOCP vs label dose — does electrolyte control hold? — LIKELY

In dogs with hypoadrenocorticism, does a reduced-dose desoxycorticosterone pivalate (DOCP) protocol vs label dosing maintain electrolyte control?

Shelf #436 · gate-verified and displayed under the developer's blinded-trial rule

LIKELY: Reduced-dose desoxycorticosterone pivalate (DOCP) maintained electrolyte control as well as label dosing in both randomised trials, and the longer-term uncontrolled series are consistent with them — no dog in those series ever needed the 2.2 mg/kg label dose. Vincent 2021 (PMID: 34114259), a randomised controlled double-blinded trial in 37 newly diagnosed dogs, compared 1.1 mg/kg every 30 days against the label 2.2 mg/kg every 30 days for 90 days: mean serum sodium-to-potassium ratios at reevaluations were ≥32 in both populations throughout, no dog in either group developed electrolyte abnormalities warranting medical treatment, and the label-dose group showed more biochemical overtreatment (plasma renin activity overly suppressed on 80.8% of control assessments; lower urine specific gravity, median 1.022 vs 1.033, P = .006). Langlois 2026 (PMID: 41742504), a randomised trial of a single injection in 21 newly diagnosed dogs, found duration of DOCP action by serum electrolytes was 58 ± 11 days at 1.1 mg/kg vs 61 ± 13 days at 2.2 mg/kg (P = .66) and by plasma renin activity 45 ± 12 vs 55 ± 16 days (P = .2), despite half the dose (overall drug exposure 19.6 vs 32.1 day × ng/mL). Longer-term uncontrolled support points the same way: Sieber-Ruckstuhl 2019 (PMID: 30865322), a prospective series of 17 dogs started at 1.5 mg/kg, needed a median final dose of only 1.1 mg/kg (range 0.7–1.8) over a median 16.2 months and no dog ever needed 2.2 mg/kg; Bates 2013 (PMID: 23438457), a retrospective series of 49 dogs (36 started below 2.2 mg/kg), found no dog developed uncontrolled hypoadrenocorticism or severe electrolyte abnormalities requiring a dose increase. Design class (a): Vincent 2021 establishes both randomisation (computer-generated randomization log, full text) and double-blinding answering this shelf's own comparison (1.1 vs 2.2 mg/kg every 30 days) in this shelf's own population (newly diagnosed primary hypoadrenocorticism); Langlois 2026 also states computer-generated randomisation, with partial masking — the technician who administered the injection at each site was unblinded (a dedicated research technician at one site, a single clinical technician at the other), and all other personnel including clinicians, investigators, hospital staff and clients remained blinded. The stamp is LIKELY rather than PROBABLE because the decisive trial is small (37 dogs), short (90 days), uses electrolyte surrogates rather than crisis outcomes, and prespecifies no non-inferiority margin in its record. Near-miss, not carded: Münch 2020 (PMID: 32557492), a retrospective German-language series of 13 dogs started at 1.5 mg/kg, all clinically healthy after the first or second injection with last documented doses ≤1.6 mg/kg — consistent with the carded series but uncontrolled and duplicative of Sieber-Ruckstuhl 2019. Species boundary: Sieber-Ruckstuhl 2023 (PMID: 36809682) is a feline hypoadrenocorticism series (cats needed higher doses) and is not evidence for this canine shelf. Tier C adjudication, recorded on the face: Tier C is NOT engaged — no carded record makes a mortality or survival-PRIMARY benefit claim; Bates 2013 analysed survival against initial dose as a secondary/safety question and found no statistically significant relationship, a null finding with no benefit claimed, which does not engage Tier C. Drafted Nov 10, 2026 (VetMed build, topic #436); figures from the abstracts and the PMC full texts (Vincent 2021, Langlois 2026, Sieber-Ruckstuhl 2019) fetched and verified at drafting.

Vincent 2021: low-dose DOCP 1.1 mg/kg q30d maintained electrolyte control as well as label 2.2 mg/kg q30d over 90 days in a randomised double-blinded trial — no dog in either group needed treatment for electrolyte abnormalities, and label dosing over-suppressed renin on 80.8% of assessments

Randomized Controlled Trial, Veterinary (the record's own publication types: Journal Article, Randomized Controlled Trial, Veterinary), described in the record as a 'Randomized controlled double-blinded clinical trial'. Randomisation is stated (computer-generated randomization log in the full text) and double-blinding is stated.

Who: Dogs: 37 dogs with newly diagnosed primary glucocorticoid- and mineralocorticoid-deficient hypoadrenocorticism — 19 test-population dogs on low-dose DOCP 1.1 mg/kg SC approximately every 30 days and 18 control dogs on standard (label) dose 2.2 mg/kg SC approximately every 30 days, followed for 90 days with clinical and laboratory assessment 10 to 14 days and approximately 30 days after each treatment. Design facts (full text): assignment in double-blinded fashion using a computer-generated randomization log; treatment group unmasked only after the day 90 evaluation; one control dog withdrew after day 30 (data to day 30 included).

Result: Mean serum sodium to potassium ratios at reevaluations were ≥32 in both populations throughout the study. No dog developed electrolyte abnormalities warranting medical treatment, although hypokalemia occurred on at least 1 occasion in 9 controls and 6 test population dogs. Urine specific gravities (median, interquartile range) were lower in control dogs (1.022, 1.016-1.029) as compared to test population dogs (1.033, 1.023-1.039; P = .006). Plasma renin activity was overly suppressed on 84 of 104 (80.8%) assessments in control dogs whereas increased renin activity occurred on 23 of 112 (20.5%) assessments in test population dogs. The authors conclude low-dose DOCP protocols appear to be safe and effective for treatment of hypoadrenocorticism in most dogs, and standard-dose protocols are more likely to result in biochemical evidence of overtreatment.

Watch out: SMALL, SHORT AND SURROGATE-BASED: 37 dogs and 90 days, powered on detecting a sodium-to-potassium ratio difference of 2.5 rather than on a prespecified non-inferiority margin or on Addisonian crises, so 'no dog needed rescue treatment' is reassuring but not proof of equal safety over years. Hypokalemia occurred on at least one occasion in both groups (9 of 18 controls, 6 of 19 low-dose dogs — counts of dogs, from the record), and only newly diagnosed dogs were studied; dogs stabilised long-term or with atypical disease were not tested.

Vincent AM, Okonkowski LK, Brudvig JM, Refsal KR, Berghoff N, Olivier NB, Langlois DK. Low-dose desoxycorticosterone pivalate treatment of hypoadrenocorticism in dogs: A randomized controlled clinical trial. J Vet Intern Med. 2021;35(4):1720-1728. PMID: 34114259. Registry ID: none in the record. MeSH: Adrenal Insufficiency*/veterinary · Animals · Desoxycorticosterone/adverse effects, analogs & derivatives · Dog Diseases*/drug therapy · Dogs · Mineralocorticoids/therapeutic use

Langlois 2026: after a single injection, DOCP's duration of action by electrolytes was 58 ± 11 days at 1.1 mg/kg vs 61 ± 13 days at 2.2 mg/kg (P = .66) in a randomised trial — half the dose, essentially the same duration of electrolyte control

Randomized Controlled Trial, Veterinary (the record's own publication types: Journal Article, Randomized Controlled Trial, Veterinary), described in the record as a prospective clinical trial with random assignment. Randomisation is stated (computer-generated randomization log); blinding is partial — all personnel remained blinded except the technician who administered the injection at each site (a dedicated research technician at MSU-VMC; a single clinical technician at Greater Lansing Veterinary Center).

Who: Dogs: 21 dogs with newly diagnosed hypoadrenocorticism with concurrent mineralocorticoid deficiency (11 castrated males, 9 spayed females, 1 intact male; mixed breed n = 6, Standard Poodle-crosses n = 4, Labrador Retrievers n = 4 most common), given a single SC injection of low-dose DOCP 1.1 mg/kg (n = 11) or label-dose 2.2 mg/kg (n = 10) and re-evaluated on days 1, 7, 10, 14, 21, 28 and weekly thereafter until abnormal serum electrolyte profiles recurred; all dogs also received prednisone throughout. Design facts (full text): random assignment using a simple computer-generated randomization log (Microsoft Excel) created by a dedicated research technician; partial masking — the injection was administered by a dedicated research technician (MSU-VMC cases) or a single clinical technician (Greater Lansing Veterinary Center cases), and all other personnel including clinicians, investigators, hospital staff and clients remained blinded to treatment group for the study duration.

Result: Maximum drug concentrations and overall drug exposures were higher in label-dose dogs (1.22 ± 0.46 ng/mL and 32.1 ± 12.3 day × ng/mL) than in low-dose dogs (0.69 ± 0.32 ng/mL and 19.6 ± 5.3 day × ng/mL; P = .008 for both comparisons). The durations of DOCP action (mean ± SD) determined by serum electrolyte concentrations in 8 low-dose dogs (58 ± 11 days) and 7 label-dose dogs (61 ± 13 days) were not significantly different (P = .66). Similarly, the durations of DOCP action determined by plasma renin activity in 8 low-dose dogs (45 ± 12 days) and 7 label-dose dogs (55 ± 16 days) were not significantly different (P = .2). Serum electrolyte concentrations overestimated the duration of action in the combined group by a mean of 10 days when compared with plasma renin activity (P < .001). Durations of overtreatment determined by serum electrolytes were median 0 days (range 0–28) in low-dose dogs and median 5 days (range 0–25) in label-dose dogs (P = .74). The authors conclude low-dose DOCP administered every 5–7 weeks is a reasonable treatment strategy for most dogs, and that prolonging dosing intervals beyond 7–8 weeks based solely on electrolyte concentrations should be avoided.

Watch out: SINGLE-INJECTION DURATION STUDY, NOT A REPEATED-DOSING TRIAL: duration of action was determinable in only 15 of 21 dogs (6 were withdrawn before it could be determined), 2 label-dose dogs with unusual pharmacokinetics were excluded from the overtreatment analysis, and 'duration' was inferred from recurrence of electrolyte abnormalities or renin changes rather than from clinical decompensation. It supports the pharmacology behind reduced dosing and longer intervals; the repeated monthly-dosing evidence is Vincent 2021. Note also the caution in its own conclusion: electrolytes overestimate true duration of action by about 10 days against renin.

Langlois DK, Dirikolu L, Brudvig JM, Lehner AF, Nelms LL, Carey SA, Jablonski SA, Cridge H, Bassiouny E, Zyskowski J, Buchweitz JP. Pharmacokinetics and pharmacodynamics of desoxycorticosterone pivalate in dogs with hypoadrenocorticism. J Vet Intern Med. 2026;40(1). PMID: 41742504. Registry ID: none in the record. MeSH: Animals · Dogs · Female · Male · Adrenal Insufficiency*/drug therapy, veterinary · Desoxycorticosterone*/analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use, analogs & derivatives · Dog Diseases*/drug therapy, blood · Dose-Response Relationship, Drug · Electrolytes/blood · Prospective Studies · Renin/blood

Sieber-Ruckstuhl 2019: a prospective low-dose DOCP protocol starting at 1.5 mg/kg controlled electrolytes in 17 dogs over a median 16.2 months — median final dose 1.1 mg/kg (range 0.7–1.8) and no dog ever needed the 2.2 mg/kg label dose

Journal Article (the record's own publication type), described in the record as a prospective study (MeSH: Prospective Studies). No randomisation and no blinding are stated, and there is no comparator arm — design class (c) for this card.

Who: Dogs: 17 client-owned dogs with naturally occurring primary hypoadrenocorticism (12 newly diagnosed, started on DOCP 1.5 mg/kg SC; 5 previously treated with fludrocortisone acetate, started on DOCP 1.0–1.8 mg/kg SC), followed prospectively for a minimum of 3 months with clinical examination and serum sodium and potassium measurement at regular intervals, the dose adjusted to obtain an injection interval of 28–30 days and keep electrolytes within the reference interval. Design facts: prospective single-protocol series — no label-dose comparator arm, no randomisation and no blinding stated.

Result: Median (range) follow-up was 16.2 months (4.5–32.3 months). The starting dosage was sufficient in all but 2 dogs and had to be significantly decreased after 2–3 months to a median dosage (range) of 1.1 mg/kg (0.7–1.8). Dogs 3 years of age or younger needed significantly higher dosages compared to older dogs. None of them, however, needed the 2.2 mg/kg DOCP dosage recommended by the manufacturer. The authors conclude a starting dosage of 1.5 mg/kg DOCP is effective in controlling clinical signs and serum electrolyte concentrations in the majority of dogs with primary hypoadrenocorticism, and that an additional dose reduction often is needed to maintain an injection interval of 28–30 days.

Watch out: NO COMPARATOR: doses were titrated to each dog's electrolytes and injection interval, so the study shows a low-dose PROTOCOL with monitoring can hold control long-term, not that a fixed low dose equals label dosing in unmonitored dogs. Two of 17 dogs needed more than the starting dose, young dogs (≤3 years) needed significantly higher doses than older dogs, and 5 dogs entered from fludrocortisone rather than newly diagnosed — dose requirements are individual and monitoring is part of the intervention.

Sieber-Ruckstuhl NS, Reusch CE, Hofer-Inteeworn N, Kuemmerle-Fraune C, Müller C, Hofmann-Lehmann R, Boretti FS. Evaluation of a low-dose desoxycorticosterone pivalate treatment protocol for long-term management of dogs with primary hypoadrenocorticism. J Vet Intern Med. 2019;33(3):1266-1271. PMID: 30865322. Registry ID: none in the record. MeSH: Addison Disease/drug therapy, economics, veterinary* · Age Factors · Animals · Desoxycorticosterone/administration & dosage, analogs & derivatives*, economics, therapeutic use · Dog Diseases/drug therapy*, economics · Dogs · Female · Male · Mineralocorticoids/administration & dosage*, economics, therapeutic use · Potassium/blood · Prospective Studies · Sodium/blood

Bates 2013: in a retrospective series of 49 dogs, initial DOCP doses below the 2.2 mg/kg label dose (36 dogs) were not followed by uncontrolled disease or severe electrolyte abnormalities requiring a dose increase

Journal Article (the record's own publication type), described in the record as a retrospective study (MeSH: Retrospective Studies). No randomisation and no blinding are stated — design class (c) for this card.

Who: Dogs: 49 dogs with primary hypoadrenocorticism treated with DOCP, including 36 with initial doses less than 2.2 mg/kg, in a retrospective medical-record review with telephone follow-up of owners or veterinarians to determine date of death or last follow-up. Design facts: retrospective study — no randomisation and no blinding; initial dose varied at clinician discretion and most dogs' mg/kg dose fell over time because of weight gain during treatment.

Result: Regardless of their initial DOCP dose, none of the dogs developed uncontrolled hypoadrenocorticism or severe electrolyte abnormalities or clinical problems that would have made an increase in the DOCP dose necessary. Over time, most dogs had a decrease in their DOCP dose in mg/kg, because of weight gain during treatment. No statistically significant relationships were found between initial DOCP dose and survival or post-treatment serum Na, K or Na:K, with the exception of one statistically significant result that suggested lower efficacy for higher doses. The authors conclude initial DOCP doses less than 2.2 mg/kg may be effective in controlling serum electrolyte concentrations in dogs with primary hypoadrenocorticism without adversely affecting survival.

Watch out: RETROSPECTIVE AND DOSE-DRIFTING: initial doses were clinician-chosen (confounding by indication is possible), doses changed over time, and follow-up for survival was by telephone. Tier C note recorded on the face: the survival analysis here is a secondary, null association (no significant relationship between initial dose and survival) with no survival benefit claimed by anyone — it is a safety observation, not a mortality-benefit claim, and does not engage Tier C.

Bates JA, Shott S, Schall WD. Lower initial dose desoxycorticosterone pivalate for treatment of canine primary hypoadrenocorticism. Aust Vet J. 2013;91(3):77-82. PMID: 23438457. Registry ID: none in the record. MeSH: Adrenal Insufficiency/blood, drug therapy, veterinary* · Animals · Desoxycorticosterone/adverse effects, analogs & derivatives, therapeutic use* · Dog Diseases/blood, drug therapy* · Dogs · Dose-Response Relationship, Drug · Electrolytes/blood · Female · Hydrocortisone/blood · Male · Mineralocorticoids/adverse effects, therapeutic use* · Retrospective Studies · Treatment Outcome

Synthesis: half-dose DOCP (about 1.1 mg/kg monthly) held electrolyte control as well as the 2.2 mg/kg label dose in randomised blinded comparisons, with less biochemical overtreatment — long-term series never needed the label dose

Synthesis

Who: Dogs: synthesis of the four carded records in dogs with primary hypoadrenocorticism — two randomised dose-comparison trials in newly diagnosed dogs (Vincent 2021, 37 dogs, repeated monthly dosing for 90 days; Langlois 2026, 21 dogs, single injection followed to electrolyte recurrence), one prospective low-dose protocol series (Sieber-Ruckstuhl 2019, 17 dogs, median 16.2 months) and one retrospective dose series (Bates 2013, 49 dogs).

Result: No dog in the randomised monthly-dosing trial needed rescue treatment for electrolyte abnormalities, and no dog in the retrospective series required a dose increase; in the prospective titration series 2 of 17 dogs needed a modest increase (to 1.6–1.7 mg/kg), still below the label dose, and no dog in any record ever needed 2.2 mg/kg. The blinded monthly-dosing trial kept mean sodium-to-potassium ratios ≥32 in both dose groups, and the single-injection trial found near-identical electrolyte-based duration of action (58 vs 61 days). The consistent counter-signal is overtreatment at label dose (renin over-suppression, lower urine specific gravity). The shelf is stamped LIKELY: the evidence is direct, randomised and concordant, but the decisive trial is small and short with electrolyte surrogates, so individual electrolyte monitoring remains part of any reduced-dose protocol.

Watch out: Reduced dose is not reduced monitoring: every carded protocol rechecked electrolytes (10–14 days and at each injection in the trials; regular re-evaluation in the series), young dogs needed higher doses in the prospective series, and Langlois 2026 warns electrolytes alone overestimate DOCP's true duration of action by about 10 days against renin — do not stretch intervals beyond 7–8 weeks on electrolytes alone.

Synthesis of Vincent et al. PMID: 34114259; Langlois et al. PMID: 41742504; Sieber-Ruckstuhl et al. PMID: 30865322; Bates et al. PMID: 23438457. Registry IDs as on the individual cards (none in the records).

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.